Supports development of vaccines 1) to address antibiotic resistant gram-negative bacteria focusing on but not limited to Burkholderia spp., Pseudomonas aeruginosa, Francisella tularensis, Yersinia pestis, and E. coli, and 2) for emerging viruses and pandemic preparedness that includes but is not limited to alphaviruses (e.g., Eastern Equine Encephalitis) and bunyaviruses (e.g., Rift Valley Fever Virus).
Due Date: April 9, 2020, by 3 p.m. Eastern Time
Learn more about this opportunity in here.
Global Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.